The Association Between a Family History of Type 2 Diabetes and Coronary Artery Disease in a Type 1 Diabetes Population

Diabetes Care ◽  
1998 ◽  
Vol 21 (4) ◽  
pp. 610-614 ◽  
Author(s):  
J. R. Erbey ◽  
L. H. Kuller ◽  
D. J. Becker ◽  
T. J. Orchard
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Type 1 Diabetes ◽  
Coronary Artery ◽  
Family History ◽  
History Of ◽  
Artery Disease

Family history of type 2 diabetes is increased in patients with type 1 diabetes

2008 ◽  
Vol 82 (1) ◽  
pp. e1-e4 ◽  
Author(s):  
B. Barone ◽  
M. Rodacki ◽  
L. Zajdenverg ◽  
M.H. Almeida ◽  
C.A. Cabizuca ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Family History ◽  
History Of

Family history of Type 1 diabetes affects insulin secretion in patients with ‘Type 2’ diabetes

2013 ◽  
Vol 30 (5) ◽  
pp. e163-e169 ◽  
Author(s):  
V. M. Lundgren ◽  
M. K. Andersen ◽  
B. Isomaa ◽  
T. Tuomi
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Insulin Secretion ◽  
Family History ◽  
History Of

scholarly journals Diabetes onset before age 40: more and more often it is type 2 diabetes

ABOUTOPEN ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. 126-128
Author(s):  
Viola Sanga
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Family History ◽  
Young Age ◽  
Family History Of Diabetes ◽  
Diabetes Onset ◽  
History Of

An increase in the appearance of diabetes mellitus at young age is observed, and not necessarily type 1 diabetes is involced. We report the case of a 35-year-old patient, with a family history of diabetes, with type 2 diabetes at onset (Diabetology).

scholarly journals Evaluation of Disease Complications Among Adults With Type 1 Diabetes and a Family History of Type 2 Diabetes in Taiwan

2021 ◽  
Vol 4 (12) ◽  
pp. e2138775
Author(s):  
Chia-Hung Lin ◽  
Fu-Sung Lo ◽  
Yu-Yao Huang ◽  
Jui-Hung Sun ◽  
Szu-Tah Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Family History ◽  
History Of

Abstract 15659: Screening of Coronary Artery Disease Among the Young Patients With Type 2 Diabetes

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Sirous Darabian ◽  
Bahram Khazai ◽  
Yanting Luo ◽  
Nasim Sheidaee ◽  
Anas Alani ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Ct Angiography ◽  
Cardiac Ct ◽  
Diabetic Patients ◽  
Cardiac Ct Angiography ◽  
History Of ◽  
Artery Disease

Introduction: Over the last decade, the prevalence of Type 2 diabetes (T2DM) has been significantly increased among the young population. However, the appropriate age to institute statin therapy for treatment of coronary artery disease (CAD) among this population is yet to be defined. In this study, we sought to examine the prevalence, and severity of CAD among the young T2DM population. Methods: We enrolled asymptomatic patients within the age range of 25 to 40 who underwent cardiac computed tomography (cardiac CT). Patients with type 1 diabetes, with history of less than 5 years T2DM, or with a history of stent or bypass were excluded. On the day of cardiac CT, self-reported demographic data was collected. All contrast and non-contrast enhanced cardiac CTs were reviewed by two certified expert cardiologists. Results: Total of 233 cases with an average age of 35.9 were enrolled. In this population, 38.6% were female, 167 cases (71.7%) were non-diabetic, and 55 cases (25.3%) had abnormal CAC score. There was a very strong trend towards increased prevalence of abnormal CAC score between diabetic and non-diabetic groups (33.8% vs 21.7%, respectively; p=0.06). Based on the cardiac CT angiography, 56.9% of young T2DM patients had coronary atherosclerosis which was significantly greater in comparison to the non-diabetic group (56.9% vs. 35.8%, p=0.007). Regression analyses adjusted for age, gender, dyslipidemia, hypertension, smoking, and family history of premature CAD, showed significantly greater risk of having CAD in T2DM group (OR=3.28, 95% CI: 1.30, 8.29,p<0.05). Both the severity of stenosis and number of involved segments were also significantly greater among T2DM cases. There was no gender or race specific difference in the prevalence of CAD among diabetic patients. Average of CT angiographies’ radiation dose was 2.45 milliSieverts (range:0.8-10.2 mSv). Conclusions: In total, more than half of 25-40 years old patients with history for at least 5 years of T2DM had CAD. The difference between positive CAC and CAD by CTA angiography indicates a high prevalence of soft plaques. With mean doses of approximately 2 millisieverts, cardiac CT angiography needs to be considered as a screening method for young T2DM patients.

scholarly journals Family history of type 2 diabetes and characteristics of children with newly diagnosed type 1 diabetes

Diabetologia ◽  
2020 ◽  
Author(s):  
Anna Parkkola ◽  
◽  
Maaret Turtinen ◽  
Taina Härkönen ◽  
Jorma Ilonen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Family History ◽  
Positive Family History ◽  
Newly Diagnosed ◽  
Family History Of Diabetes ◽  
The Family ◽  
History Of

Abstract Aims/hypothesis Shared aetiopathogenetic factors have been proposed in type 1 diabetes and type 2 diabetes and both diseases have been shown to cluster in families. Characteristics related to type 2 diabetes have been described in patients with type 1 diabetes with a positive family history of type 2 diabetes. We wanted to characterise the family history of type 2 diabetes and its possible effects on the phenotype and genotype of type 1 diabetes in affected children at diagnosis. Methods A total of 4993 children under the age of 15 years with newly diagnosed type 1 diabetes from the Finnish Pediatric Diabetes Register were recruited (56.6% boys, median age of 8.2 years) for a cross-sectional, observational, population-based investigation. The family history of diabetes at diagnosis was determined by a structured questionnaire, and markers of metabolic derangement, autoantibodies and HLA class II genetics at diagnosis were analysed. Results Two per cent of the children had an immediate family member and 36% had grandparents with type 2 diabetes. Fathers and grandfathers were affected by type 2 diabetes more often than mothers and grandmothers. The children with a positive family history for type 2 diabetes were older at the diagnosis of type 1 diabetes (p < 0.001), had higher BMI-for-age (p = 0.01) and more often tested negative for all diabetes-related autoantibodies (p = 0.02). Conclusions/interpretation Features associated with type 2 diabetes, such as higher body weight, older age at diagnosis and autoantibody negativity, are more frequently already present at the diagnosis of type 1 diabetes in children with a positive family history of type 2 diabetes. Graphical abstract

scholarly journals Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease with a history of PCI: an economic evaluation of THEMIS-PCI using a Swedish healthcare perpective

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
P Steg ◽  
D.L Bhatt ◽  
S.K James ◽  
O Darlington ◽  
L Hoskin ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Cost Effective ◽  
Funding Source ◽  
History Of ◽  
Artery Disease

Abstract Background The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) evaluated ticagrelor compared to placebo for the prevention of myocardial infarction (MI), stroke and cardiovascular (CV) death in 19 220 patients with type 2 diabetes (T2DM) and stable coronary artery disease (CAD) with no prior myocardial infarction (MI) or stroke. THEMIS-PCI was a pre-specified subgroup of 11 154 patients who had a history of percutaneous coronary intervention (PCI) when entering the study. In THEMIS, ticagrelor reduced CV death, MI or stroke, although with an increase in major bleeding compared to aspirin alone, and there was a significant interaction between a prior history of PCI and the net benefit of ticagrelor. In the THEMIS-PCI population, ticagrelor plus aspirin provided a favourable net clinical benefit with a significant 15% reduction in all-cause death, MI, stroke, fatal bleed, or intracranial haemorrhage. Objective The objective of this analysis was to estimate the cost-effectiveness of ticagrelor for the prevention of CV events based on the results of the THEMIS-PCI population using a lifetime horizon from a Swedish healthcare perspective. Methods A lifetime Markov state transition model was developed with health states aligned to the THEMIS trial endpoints. Health state transitions were informed by parametric survival equations fitted to patient level data from THEMIS-PCI population. Treatment discontinuation rates were informed by the THEMIS-PCI population, with all patients assumed to discontinue treatment with ticagrelor after four years. The incidence of bleeding and dyspnoea were modelled as adverse events. Costs (2019 Euros) and utility data were derived from the published literature and the THEMIS-PCI population, respectively, and discounted at 3.0% annually. Probabilistic (PSA) and deterministic sensitivity analysis (DSA) were conducted to quantify uncertainty of key input parameters. Results Treatment with ticagrelor plus aspirin over four years resulted in estimated Quality Adjusted Life Year (QALY) gains of 0.09 at an incremental cost of €1,891 compared to aspirin alone. The estimated incremental cost-effectiveness ratio (ICER) was €19,959/QALY. PSA indicated that ticagrelor was cost-effective in 93% of simulations using a willingness-to-pay threshold of €47,000/QALY and DSA showed that cost-effectiveness was robust to changes in key input parameters (ICER range: €16,504 to €25,012/QALY). Conclusion Based on the results of the THEMIS trial, dual antiplatelet therapy with ticagrelor plus aspirin is likely to be a cost-effective treatment compared with aspirin alone for the prevention of CV events in patients with T2DM and CAD with a history of PCI. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): AstraZeneca

Sign in / Sign up

Export Citation Format

Share Document